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ABSTRACT 
Graft Versus Host Disease (GVHD) is an inflammatory immune disease, mediated by the donor’s immune cells and can 
arise after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for the treatment of hematologic malignancies. It 
can lead to destructive manifestations in various tissues, particularly dermatological, gastrointestinal, and ocular tissues. 
The most common ocular morbidity is dry eyes, which is often the first manifestation of GVHD. Regulatory T cells (Tr) can 
be broadly classified as natural or adaptive (induced). After Bone-Marrow Transplantation (BMT), excessively increased 
levels of type 1 Tr (Tr1) are generally observed with absence of a GVHD, while low levels are seen with severe GVHD. 
Treatment of patients, undergoing BMT with Interleukin-10 (IL-10)-anergized donor T cells, led to immune reconstitution 
without the development of GVHD, which resulted in protection against infection and against the return of the cancer. 
Surprisingly, in both naive syngeneic mouse models of skin and cardiac allografts, graft retention was augmented after 
infusion of in vitro generated double-negative Tr (DN Tr). In addition, GVHD was reduced in mice with a genetic 
deficiency in the IL-27 receptor (IL-27R-/-) and in mice treated with anti-IL-27p28–specific antibody. Considering above 
mentioned findings we would suggest carrying out experiments, using animal models of GVHD, in order to evaluate the 
potential role of Tr, as an innovative approach to overcome severe ocular morbidity caused by ocular GVHD. 
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INTRODUCTION
Graft Versus Host Disease (GVHD) is an inflammatory 
immune disease mediated by the donor’s immune cells, 
and can lead to the destruction of various host tissues 
[1]. Surprisingly, genetic dissimilarities between host and 
donor has proved to be ineffective for identification of 
auto-epitopes in this immune disease [2]. It can manifest 
either as acute or chronic GVHD (aGVHD and cGVHD, 
respectively), which are differentiated from each other 
according to their clinical manifestations. In 12% to 17% 
of patients with aGVHD, ocular manifestations occur, 
such as acute hemorrhagic conjunctivitis and 
pseudomembranous conjunctivitis. Exceedingly complex 
immunopathological mechanisms have been recognized 
for clinical features of cGVHD, and role of donor B and T 
cells besides other immune effector cells has been 
proven [3-5]. The GVHD can arise after allogeneic 
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Hematopoietic Stem Cell Transplantation (HSCT) for the 
treatment of hematologic malignancies. This occurs 
because of a reaction against allo-antigens on the surface 
of the recipient’s cells, similar to the beneficial graft-
versus-tumor reaction, initiated by the donor’s immune 
cells against cancer cells [6, 7]. Once initiated, it can lead 
to destructive manifestations in various tissues, 
particularly dermatological, gastrointestinal, and ocular 
tissues. The most common ocular morbidity is dry eyes, 
which is often the first manifestation of GVHD. However, 
severe forms of GVHD can be lethal [4, 8]. 
Following the discovery of regulatory T cells (Tr), in 1995, 
as a subpopulation of CD25
+
CD4
+
T cells, immunologists 
suspected that these effector T cells had a suppressive 
role due to their expression of CD25. In 2003, the 
Forkhead Box P3 (FOXP3) transcription factor was 
identified as an essential marker of a subset of Tr that 
played a suppressive role in the immune system [9]. In 
general, Tr can be broadly classified as natural or 
adaptive (induced). Both of these cell types are 
responsible for preserving self-tolerance and preventing 
excessive immune responses against foreign antigens. 
After Bone-Marrow Transplantation (BMT), excessively 
increased levels of type 1 Tr (Tr1) are generally observed 
with absence of aGVHD, while low levels are seen with 
severe GVHD. Therefore, a growing number of trials have 
been investigating the potential role of Tr1 for both 
treating and preventing GVHD after BMT. To achieve this 
goal, treatment of patients undergoing BMT with 
Interleukin 10 (IL-10)-anergized donor T cells has been 
explored [10]. This treatment has been found to lead to 
immune reconstitution without the development of 
GVHD, which resulted in protection against infection and 
against the return of cancer [10]. 
In rodents, there is a special type of Tr, CD4
-
CD8
-
CD3
+
Tr, 
which is known as double-negative Tr (DN Tr). These cells 
exhibit unique surface markers, including CD69, CD45, 
CD30, CD62L, CD25, lymphocyte function-associated 
antigen 1 (LFA-1), T-cell receptor alpha/beta (TCRαβ), 
and cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4). Once activated, the cells can produce Tumor Necrosis 
Factor-alpha (TNF-α), Interferon-gamma (INF-γ), and 
Transforming Growth Factor-beta (TGF-β). In vitro and in 
vivo investigations have revealed the suppressive role of 
DN Tr on CD8
+
 and CD4
+
 T cell responses. Surprisingly, in 
both naive syngeneic mouse models of skin and cardiac 
allografts, graft retention was augmented after infusion 
of in vitro-generated DN Tr [11, 12]. 
In another animal study, GVHD was reduced in mice with 
a genetic deficiency in the IL-27 receptor (IL-27R
-/-
) and in 
mice treated with anti-IL-27p28–specific antibody. 
Further investigations revealed that shifting the donor T-
cell immune response away from pathogenic 
Tbet
+
CD4
+
type 1 T-helper cells and CD8
+
type 1 cytotoxic 
T cells, and towards CD4
+
 and CD8
+
 FOXP3-expressing Tr, 
significantly reduces GVHD grading in mice. In addition, 
an in vivo IL-27 blockade did not adversely affect IL-10 
production by Tr and enhanced the stability of these cells 
during GVHD in mice [13]. Considering its evident efficacy 
in vitro and in animal models, a growing number of in 
vivo studies are currently applying Tr as a cell therapy in 
GVHD [14, 15]. 
IMPLICATIONS 
Considering the above-mentioned findings, the current 
authors recommend carrying out experiments, using 
animal models of GVHD, in order to evaluate the 
potential role of Tr, as an innovative approach to 
overcome severe ocular morbidity caused by ocular 
GVHD. 
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